Revenue segments as reported by the company.

Premium and service revenues

Premium tax

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Depreciation

Amortization of acquired intangible assets

Premium tax expense

Health insurer fee expense

Impairment

Legal settlement

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Centene

Centene Corp. operates as a healthcare enterprise, which engages in the provision of programs and services to government sponsored healthcare programs. It operates through the following segments: Managed Care and Specialty Services. The Medicaid Managed Care segment provides health plan coverage to individuals through government subsidized programs through Medicaid. The Specialty Services segment offers healthcare services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company was founded in 1984 and is headquartered in St. Louis, MO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Centene exceeds earnings guidance, eyes growth in Marketplace products

Centene's Q4 2022 earnings call highlighted robust financial performance, successful execution of value-creation plans, and a focus on operational efficiency. While challenges in Medicare Advantage margins are anticipated, opportunities in the Marketplace business and cost-cutting initiatives offer avenues for growth. Strategic initiatives to address demographic shifts and enhance care relationships position Centene for future success.

Centene reports strong Q1 earnings, focuses on growth opportunities

Centene's Q1 performance reflects strength in financial results and a strategic outlook for future growth.
Despite challenges in Medicare profitability and Medicaid redeterminations, Centene remains focused on maximizing membership and maintaining high margins.
Opportunities in enhancing relationships, investing in infrastructure, and updating margin assumptions position Centene for long-term success.

Centene reports strong Q2 earnings, raises 2023 outlook amidst challenges

Centene's Q2 earnings call showcased robust financial performance, operational efficiencies, and strategic wins in Medicaid and Marketplace segments. While facing challenges in cost trends and Star ratings strategy, the company is well-positioned for growth through revenue expansion and value-creation initiatives. Opportunities for engagement with key stakeholders and successful outreach efforts present avenues for continued success.

Centene exceeds Q3 earnings expectations, eyes growth opportunities in 2024

Centene's Q3 2023 earnings call highlighted strong financial performance, progress in Medicaid redeterminations, and operational advancements. The company anticipates continued growth in adjusted EPS for 2023 and 2024, with a focus on margin expansion and operational efficiencies. Challenges include managing membership declines and addressing questions on business plans and cost implications.

Centene exceeds 2023 expectations, poised for growth in 2024

Centene's 2023 performance was strong, exceeding expectations and positioning the company for continued growth. Key initiatives in Medicaid, Medicare Advantage, and Marketplace are driving revenue growth and operational efficiency. Challenges in managing utilization trends and achieving target margins require ongoing attention.

Centene surpasses Q1 earnings expectations, eyes growth in Medicaid and Marketplace

Centene's Q1 performance exceeded expectations, showcasing strength in Medicaid and Marketplace segments.
While facing challenges in contract protests and operational clarity, the company's strategic focus on Medicare Advantage and growth opportunities remain key strengths.
With a robust financial outlook and ongoing initiatives for optimization, Centene is well-positioned for continued success in the healthcare market.
Investors can be optimistic about Centene's growth trajectory, supported by strong operational performance and strategic initiatives.

Centene reports robust Q2 earnings, eyes Medicaid rebound and Medicare growth

Centene's Q2 2024 earnings call highlighted strong performance, Medicaid challenges, and growth opportunities in Medicaid and Medicare markets. Leadership transitions and focus on program innovation are key areas of development for the company.

Centene surpasses Q3 earnings expectations, eyes growth amid challenges

Centene's Q3 performance exceeded expectations, driven by improvements in Medicaid and strong Medicare and Marketplace segments.
Despite challenges in Medicaid and competitive pressures, Centene remains confident in its future growth and operational enhancements.
The company's strategic focus on AI, margin expansion, and quality improvement positions it well for continued success and profitability.
Analyst inquiries and company responses highlighted key areas of focus and potential areas for improvement and growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Centene Corp. is a healthcare enterprise, which engages in the provision of programs and services to government sponsored healthcare programs. It operates through the following segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment includes the Temporary Assistance for Needy Families program, Medicaid Expansion programs, the Aged, Blind or Disabled program, the Children's Health Insurance Program, Long-Term Services and Supports, Foster Care, Medicare-Medicaid Plans, which cover beneficiaries who are dually eligible for Medicaid and Medicare, and other state-based programs. The Medicare segment consists of Medicare Advantage, Medicare Supplement, Dual Eligible Special Needs Plans, and Medicare Prescription Drug Plans. The Commercial segment is involved in the Health Insurance Marketplace product along with individual, small group, and large group commercial health insurance products. The Other segment refers to pharmacy operations, Envolve Benefit Options’ vision and dental services, clinical healthcare, behavioral health, international operations, and corporate management companies. The company was founded in 1984 and is headquartered in St. Louis, MO.

ST. LOUIS, Dec. 30, 2020 /PRNewswire/ -- Centene Corporation (NYSE: CNC) today announced that it has completed its acquisition of PANTHERx, one of the largest and fastest-growing specialty pharmacies in the United States specializing in orphan drugs and treating rare diseases. "We are...

Centene Completes Acquisition of PANTHERx Rare Pharmacy (PANTHERx)

Centene (CNC) provides an impressive 2021 guidance for key metrics owing to its strong inorganic growth story and a healthy revenue stream.

Centene (CNC) Announces Solid Financial Guidance for 2021

Shares of Centene Corp. fell 1.3% in premarket trading Friday, after the provider of government-sponsored and commercial health care programs provided downbeat profit guidance for next year, but an in-line revenue outlook. The company said it expects 2021 adjusted earnings per share to rise to $5.00 to $5.30, which is below the FactSet consensus of $5.43, from $4.90 to $5.06 this year; the 2020 FactSet consensus is $4.99.

Centene stock falls after downbeat profit outlook for next year

ST. LOUIS, Dec. 18, 2020 /PRNewswire/ -- Centene Corporation (NYSE: CNC) announced today its 2021 financial guidance. Total revenues are expected to be $114.1 billion to $116.1 billion, and diluted earnings per share are expected to be $3.82 to $4.06. Adjusted diluted earnings per share...

Centene Corporation Announces 2021 Guidance

Adaptive Biotechnologies

BridgeBio Pharma Inc

Boston Scientific

Thermo Fisher Scientific

According to current portfolio statistics, a Premium feature of GuruFocus, the top five health care positions in Andreas Halvorsen (Trades, Portfolio)'s equity portfolio as of the third quarter are Adaptive Biotechnologies Corp. (NASDAQ:ADPT), Centene Corp. (NYSE:CNC), BridgeBio Pharma Inc. (NASDAQ:BBIO), Boston Scientific Corp. (NYSE:BSX) and Thermo Fisher Scientific Inc. (NYSE:TMO). This week, Halvorsen revealed a slight reduction to his Adaptive Biotechnologies position according to GuruFocus Real-Time Picks, which is also a Premium feature.

Andreas Halvorsen's Top 5 Health Care Positions as of the 3rd Quarter

Centene Corp. (NYSE:CNC) is a health insurance company that specializes in government-sponsored health care programs. In addition to Medicaid and Medicare products, it offers commercial programs and Marketplace operations.

Centene: A Modestly Undervalued Growth Stock

Centene (CNC) to buy specialty pharmacy PANTHERx Rare to penetrate the specialty drug market and cater to patients with complex situations.

Centene (CNC) to Purchase Specialty Pharmacy PANTHERx Rare

ST. LOUIS, Dec. 15, 2020 /PRNewswire/ -- Centene Corporation (NYSE: CNC) today announced it has signed a definitive agreement to acquire PANTHERx, one of the largest and fastest-growing specialty pharmacies in the United States specializing in orphan drugs and rare diseases. The...

Centene Signs Definitive Agreement to Acquire PANTHERx Rare Pharmacy (PANTHERx)

Big Lots

BellRing Brands Inc

Investors who are in search of high return investments might be interested in the three non-cyclical stocks listed below, as their earnings yields (as calculated via Joel Greenblatt's method) are outperforming the U.S. market.

A Trio of Non-Cyclical Stocks for the Value Investor

ST. LOUIS, Dec. 7, 2020 /PRNewswire/ -- Centene Corporation (NYSE: CNC) today announced that Brent Layton has been appointed to Executive Vice President, Markets, Products, International, and Chief Business Development Officer, effective January 1, 2021. Mr. Layton will continue to report...

Centene Appoints Brent Layton to Executive Vice President, Markets, Products, International, and Chief Business Development Officer

ST. LOUIS, Nov. 30, 2020 /PRNewswire/ -- Centene Corporation (NYSE: CNC) today provided an update on its upcoming 2021 Financial Guidance and Investor Meeting. In recognition of the increase in COVID-19 cases across the country, including in Missouri and St. Louis County, the company will...

Centene Provides Format Update Of Virtual 2021 Financial Guidance And Investor Meeting On December 18, 2020

ST. LOUIS, Nov. 20, 2020 /PRNewswire/ -- Centene Corporation (NYSE: CNC) will host its 2021 Financial Guidance and Investor Meeting, in a virtual format, on Friday, December 18th, 2020. Michael F. Neidorff, Chairman, President and Chief Executive Officer, and Jeffrey A. Schwaneke,...

Centene Corporation To Host Virtual 2021 Financial Guidance And Investor Meeting On December 18, 2020

Athene Holding Ltd. Class A

Cigna

Alphabet

JPMorgan Chase & Co

Leon Cooperman (Trades, Portfolio), founder and chairman of the Omega Advisors Family Office, disclosed that its top five trades for the third quarter included new holdings in Alphabet Inc. (NASDAQ:GOOG)(NASDAQ:GOOGL) and Athene Holding Ltd. (NYSE:ATH) and sells in JPMorgan Chase & Co. (NYSE:JPM), Centene Corp. (NYSE:CNC) and Cigna Corp. (NYSE:CI).

Leon Cooperman's Top 5 Trades of the 3rd Quarter

Albertsons Companies

Beazer Homes USA

Ingredion

AT&T

iShares MSCI EAFE Value ETF

Vanguard S&P 500 Value ETF

Value investing is one of the best ways investors can play the market. Warren Buffet did it -- what's stopping you?

7 Value Stocks That Could Make You the Next Warren Buffett

Centene's (CNC) Marketplace product - Ambetter undertakes technology improvements for benefiting members and new enrollees.

Centene (CNC) Marketplace Product Undergoes Technology Upgrade

Centene (CNC) inks deal to acquire Apixio for availing enhanced AI technology solutions and digitizing its administrative activities.

Centene (CNC) Acquires Apixio, Boosts Data Analytics Portfolio

Centene Corporation (NYSE: CNC) recently announced it signed a definitive agreement to buy Apixio. These are the details.

Why Centene Is Buying Apixio

ST. LOUIS, Nov. 4, 2020 /PRNewswire/ -- Centene Corporation (NYSE: CNC) announced today it will participate at two virtual conferences this month. On Tuesday, November 10, at 8:45 a.m. Eastern Standard Time (EST), Centene will participate in a virtual format at the Credit Suisse 29th...

Centene To Participate At Upcoming Conferences

Centene Corporation may not be a household name, but it is a leading provider of government-sponsored health plans. It's weathering the current pandemic well, and has seen continued membership growth.

Centene Corporation: 32% Upside For This Healthcare Insurer

Centene (CNC) could produce exceptional returns because of its solid growth attributes.

Here is Why Growth Investors Should Buy Centene (CNC) Now

Centene Corporation (CNC) CEO Michael Neidorff on Q3 2020 Results - Earnings Call Transcript

Centene's (CNC) third-quarter results reflect higher revenues and managed care membership.

Centene's (CNC) Q3 Earnings Improve Y/Y on High Revenues

Centene (CNC) delivered earnings and revenue surprises of 31.25% and 2.50%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Centene (CNC) Surpasses Q3 Earnings and Revenue Estimates

Centene, which completed its acquisition WellCare earlier this year to create a national health plan, reported revenue jumped 53% to $29 billion, putting the company on track to eclipse $109 billion in revenue for 2020.

Centene's Enrollment Jumps Thanks To WellCare And Pandemic Enrollment

ST. LOUIS, Oct. 27, 2020 /PRNewswire/ -- Centene Corporation (NYSE: CNC) announced today its financial results for the third quarter ended September 30, 2020, reporting diluted earnings per share (EPS) of $0.97 and Adjusted diluted EPS of $1.26, including the risk corridor, charitable...

News for Centene Stock (CNC)